HCW Biologics
HCWB
11 hedge funds and large institutions have $855K invested in HCW Biologics in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
67% more capital invested
Capital invested by funds: $512K → $855K (+$343K)
38% more funds holding
Funds holding: 8 → 11 (+3)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$353K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$234K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$132K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$59.8K |
| 5 |
State Street
Boston,
Massachusetts
|
+$57.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$145K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$119K |
| 3 |
Goldman Sachs
New York
|
-$63K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$18K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
-$10.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Two Sigma Investments
New York
| $289K | +$353K | +520 | New |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $191K | +$234K | +344 | New |
|
|
BCM
3
Bridgeway Capital Management
Houston,
Texas
| $108K | +$132K | +194 | New |
|
|
4
Geode Capital Management
Boston,
Massachusetts
| $98K | +$59.8K | +88 | +99% |
|
|
5
State Street
Boston,
Massachusetts
| $47K | +$57.1K | +84 | New |
|
6
BlackRock
New York
| $39K | +$1.36K | +2 | +3% |
|
|
CAM
7
Cresset Asset Management
Chicago,
Illinois
| $29K | +$35.3K | +52 | New |
|
8
Renaissance Technologies
New York
| $28K | +$34K | +50 | New |
|
|
9
HighTower Advisors
Chicago,
Illinois
| $23K | -$10.9K | -16 | -28% |
|
|
FWM
10
Focused Wealth Management
Newburgh,
New York
| $2K | +$2.72K | +4 | New |
|
11
Morgan Stanley
New York
| $1K | – | – | – |
|
|
12
Millennium Management
New York
| – | -$145K | -189 | Closed |
|
|
13
UBS Group
Zurich,
Switzerland
| – | -$119K | -156 | Closed |
|
|
14
Goldman Sachs
New York
| – | -$63K | -82 | Closed |
|
|
TRCT
15
Tower Research Capital (TRC)
New York
| – | -$18K | -24 | Closed |
|
HCWB Hedge Fund Activity: Q4 2021 in Review
11 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in HCW Biologics (HCWB) for Q4 2021, worth a combined $855K — up 67% from $512K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new HCWB positions and 4 closed out — a net gain of 3 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Two Sigma Investments, opening a new position worth an estimated $353K. The largest seller was Millennium Management, exiting entirely with an estimated $145K sold.
- 11 institutional investors held HCW Biologics (HCWB) as of Q4 2021, up from 8 in Q3 2021.
- Funds reported $855K of HCW Biologics stock for Q4 2021, up 67% quarter-over-quarter.
- 7 funds opened new HCW Biologics positions in Q4 2021 and 4 closed out, a net change of +3 holders.
- The largest HCW Biologics buyer in Q4 2021 was Two Sigma Investments, an estimated $353K added.
- The largest HCW Biologics seller in Q4 2021 was Millennium Management, an estimated $145K sold.
Based on aggregated 13F filings for Q4 2021.